Wyeth Hib vaccine shortage
Executive Summary
Wyeth expects to resume full supply of its Hib vaccine by the end of the year. Wyeth stopped manufacturing the product in the winter of 2002 because the supplier of its shipping vials went out of business. The company has found a new supplier and is building inventory. CDC indicated that Aventis and Merck have stepped up production to meet the supply gap; the Wyeth product represents 30% of the market...
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.